静脉唑来膦酸对膝骨关节炎伴骨髓病变患者胫股软骨体积的影响:一项随机临床试验
这项24个月多中心双盲安慰剂对照随机临床试验纳入223例有症状膝骨关节炎且MRI检出软骨下骨髓病变的50岁以上成人,比较静脉唑来膦酸5mg与安慰剂。结果显示两组24个月胫股软骨体积变化无显著差异,次要结局(膝痛与骨髓病变大小)亦无显著差异,不支持使用唑来膦酸治疗膝骨关节炎。
要点
- yearly静脉唑来膦酸未显著减少膝骨关节炎患者24个月软骨体积丢失。
- 膝痛与骨髓病变大小等预设次要结局均无显著组间差异。
- 唑来膦酸组不良事件更常见(96% vs 83%),主要为急性反应。
核心结论
- 在有症状膝骨关节炎伴骨髓病变患者中,与安慰剂相比, yearly唑来膦酸输注未显著减少24个月软骨体积丢失。
- 这些发现不支持使用唑来膦酸治疗膝骨关节炎。
研究设计与样本
- 24个月多中心、双盲、安慰剂对照随机临床试验,在澳大利亚4个中心(1个研究中心和3家医院)开展。
- 纳入50岁及以上有症状膝骨关节炎且MRI检出软骨下骨髓病变的成人,2013年11月至2015年9月入组,末次随访2017年10月9日。
- 干预为基线和12个月静脉输注唑来膦酸5mg(100mL生理盐水,n=113)或安慰剂生理盐水(n=110);共223例入组,190例(85%)完成试验。
主要发现
- 24个月胫股软骨体积变化组间无显著差异:唑来膦酸组-878 mm3 vs 安慰剂组-919 mm3,组间差异41 mm3(95%CI -79至161 mm3;P=.50)。
- 24个月视觉模拟量表膝痛变化组间无显著差异:-11.5 vs -16.8,组间差异5.2(95%CI -2.3至12.8;P=.17)。
- 24个月WOMAC膝痛变化组间无显著差异:-37.5 vs -58.0,组间差异20.5(95%CI -11.2至52.2;P=.21)。
- 24个月骨髓病变大小变化组间无显著差异:-33 mm2 vs -6 mm2,组间差异-27 mm2(95%CI -127至73 mm2;P=.60)。
- 不良事件唑来膦酸组更常见(96% vs 83%),主要为急性反应(87% vs 56%)。
关键数值与推荐
- 主要结局为MRI评估的24个月胫股软骨体积绝对变化,最小临床重要差异(MCID)尚未确立。
- 预设次要结局包括膝痛视觉模拟量表(0无痛至100不可忍受痛;MCID 15)和WOMAC(0无痛至500不可忍受痛;MCID 75)在3、6、12、18、24个月的变化,以及骨髓病变大小在6和24个月的变化(MCID尚未确立)。
- 试验注册号:anzctr.org.au ACTRN12613000039785。
临床怎么用
- 对于有症状膝骨关节炎伴骨髓病变的患者,不应基于本试验结果使用 yearly静脉唑来膦酸来延缓软骨体积丢失或改善膝痛。
- 临床决策时需权衡唑来膦酸的不良事件风险,本试验中急性反应发生率较高。
局限性
- 主要结局MCID尚未确立,影响软骨体积变化的临床意义解读。
- 试验仅纳入有症状膝骨关节炎且MRI检出骨髓病变的50岁以上成人,结果外推需谨慎。
- 24个月随访期间190例(85%)完成试验,存在一定失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A proof-of-principle study suggested that intravenous zoledronic acid may reduce knee pain and the size of bone marrow lesions in people with knee osteoarthritis, but data from large trials are lacking. OBJECTIVE: To determine the effects of intravenous zoledronic acid on knee cartilage volume loss in patients with symptomatic knee osteoarthritis and bone marrow lesions. DESIGN, SETTING, AND PARTICIPANTS: A 24-month multicenter, double-blind placebo-controlled randomized clinical trial conducted at 4 sites in Australia (1 research center and 3 hospitals). Adults aged 50 years or older with symptomatic knee osteoarthritis and subchondral bone marrow lesions detected by magnetic resonance imaging (MRI) were enrolled from November 2013 through September 2015. The final date of follow-up was October 9, 2017. INTERVENTIONS: Intravenous infusion with either 5 mg of zoledronic acid in a 100-mL saline solution (n = 113) or a placebo saline solution (n = 110) at baseline and 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was absolute change in tibiofemoral cartilage volume assessed using MRI over 24 months (the minimum clinically important difference [MCID] has not been established). Three prespecified secondary outcomes were change in knee pain assessed by a visual analog scale (0 [no pain] to 100 [unbearable pain]; MCID, 15) and the Western Ontario and McMaster Universities Osteoarthritis Index (0 [no pain] to 500 [unbearable pain]; MCID, 75) over 3, 6, 12, 18, and 24 months and change in bone marrow lesion size over 6 and 24 months (the MCID has not been established). RESULTS: Of 223 participants enrolled (mean age, 62.0 years [SD, 8.0 years]; 52% were female), 190 (85%) completed the trial. Change in tibiofemoral cartilage volume was not significantly different between the zoledronic acid group and the placebo group over 24 months (-878 mm3 vs -919 mm3; between-group difference, 41 mm3 [95% CI, -79 to 161 mm3]; P = .50). No significant between-group differences were found for any of the prespecified secondary outcomes, including changes in knee pain assessed by a visual analog scale (-11.5 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference, 5.2 [95% CI, -2.3 to 12.8]; P = .17), changes in knee pain assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (-37.5 vs -58.0, respectively; between-group difference, 20.5 [95% CI, -11.2 to 52.2]; P = .21), and changes in bone marrow lesion size (-33 mm2 vs -6 mm2; between-group difference, -27 mm2 [95% CI, -127 to 73 mm2]; P = .60) over 24 months. Adverse events were more common with zoledronic acid than with placebo (96% vs 83%, respectively) and consisted mainly of acute reactions (defined as symptoms within 3 days of administration of infusion; 87% vs 56%). CONCLUSIONS AND RELEVANCE: Among patients with symptomatic knee osteoarthritis and bone marrow lesions, yearly zoledronic acid infusions, compared with placebo, did not significantly reduce cartilage volume loss over 24 months. These findings do not support the use of zoledronic acid in the treatment of knee osteoarthritis. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12613000039785.
引用
- Cai G, Aitken D, Laslett LL, et al. Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial. JAMA. 2020. PMID: 32315057. doi:10.1001/jama.2020.2938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。